Soricimed featured in BioTuesdays

Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have failed first line treatment, as well as patients with advanced pancreatic and ovarian cancers.

View full article at:

Sign up to receive updates from Soricimed

Powered by Innovasium